The Indian Journal of Pediatrics

, Volume 73, Issue 4, pp 313–321 | Cite as

New antiviral agents

  • Nahed Abdel-Haq
  • Pimpanada Chearskul
  • Hossam Al-Tatari
  • Basim Asmar
New Drugs Antibiotics


During the last three decades, a better understanding of viral replication and disease states caused by viral infections have led to the development of newer antiviral agents with enhanced activity and better tolerability. This review focuses on newer systemic and topical antiviral agents that are used in treatment of herpes viruses including herpes simplex type-1 (HSV-1) and type-2 (HSV-2), varicella-zoster virus (VZV) and cytomegalovirus CMV) as well as the human papilloma virus (HPV). Included in this article are the agents famiclovir, penciclovir, valganciclovir, imiquimod, docosanole and brivudin.

Key words

Viral infecting Systemic and topical antiviral agents Herpes viruses 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.Clin Pharmacol Ther 1993; 54(6): 595–605.PubMedCrossRefGoogle Scholar
  2. 2.
    Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine; penciclovir].Antimicrob Agents Chemother 1989;33(10): 1765–1773.PubMedGoogle Scholar
  3. 3.
    Pue MA, Pratt SK, Fairless AJ, Fowles S, Laroche J, Georgiou Pet al. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers.J Antimicrob Chemother 1994;33(1): 119–127.PubMedCrossRefGoogle Scholar
  4. 4.
    Crumpacker C. The pharmacological profile of famciclovir.Semin Dermatol 1996;15(2 Suppl 1): 14–26.PubMedGoogle Scholar
  5. 5.
    Earnshaw DL, Bacon TH, Darlison SJ, Edmonds K, Perkins RM, Vere Hodge RA. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus.Antimicrob Agents Chemother 1992;36(12): 2747–2757.PubMedGoogle Scholar
  6. 6.
    Hodge RA, Perkins RM. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) against herpes simplex virus in MRC-5 cells.Antimicrob Agents Chemother 1989;33(2): 223–229.PubMedGoogle Scholar
  7. 7.
    Boike SC, Pue MA, Freed MI, Audet PR, Fairless A, Ilson BE. et al. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment.Clin Pharmacol Ther 1994;55(4): 418–426.PubMedCrossRefGoogle Scholar
  8. 8.
    Boike SC, Pue M, Audet PR, Freed MI, Fairless A, Ilson BEet al. Pharmacokinetics of famciclovir in subjects with chronic hepatic disease.J Clin Pharmacol 1994;34(12): 1199–1207.PubMedGoogle Scholar
  9. 9.
    Vere Hodge RA, Darlison SJ, Earnshaw DL, Readshaw SA. Use of isotopically chiral [4′–13C]penciclovir and 13C NMR to determine the specificity and absolute configuration of penciclovir phosphate esters formed in HSV-1 and HSV-2 infected cells and by HSV-1-encoded thymidine kinase.Chirality 1993;5(8): 583–588.PubMedCrossRefGoogle Scholar
  10. 10.
    Boyd MR, Bacon TH, Sutton D, Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture.Antimicrob Agents Chemother 1987; 31(8): 1238–1242.PubMedGoogle Scholar
  11. 11.
    Shaw T, Amor P, Civitico G, Boyd M, Locarnini S. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus.Antimicrob Agents Chemother 1994;38(4): 719–723.PubMedGoogle Scholar
  12. 12.
    Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng Met al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group.Ann Intern Med 1995;123(2): 89–96.PubMedGoogle Scholar
  13. 13.
    Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients.International Journal of Antimicrobial Agents 1994(4): 241–246.CrossRefPubMedGoogle Scholar
  14. 14.
    Cirelli R, Herne K, McCrary M, Lee P, Tyring SK. Famciclovir: review of clinical efficacy and safety.Antiviral Res 1996;29(2–3): 141–151.PubMedCrossRefGoogle Scholar
  15. 15.
    Romanowski B, Aoki FY, Martel AY, Lavender EA, Parsons JE, Saltzman RL. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group.Aids 2000;14(9): 1211–1217.PubMedCrossRefGoogle Scholar
  16. 16.
    Famciclovir package insert. Available from URL: Accessed 15th September 2005.Google Scholar
  17. 17.
    Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes.Antimicrob Agents Chemother 1994;38(10): 2454–2457.PubMedGoogle Scholar
  18. 18.
    Spruance SL, Kriesel JD. Treatment of herpes simplex labialis.Herpes 2002;9(3): 64–69.PubMedGoogle Scholar
  19. 19.
    Schmid-Wendtner MH, Korting HC. Penciclovir cream—improved topical treatment for herpes simplex infections.Skin Pharmacol Physiol 2004;17(5): 214–218.PubMedCrossRefGoogle Scholar
  20. 20.
    Boyd MR, Safrin S, Kern ER. Penciclovir—a review of its spectrum of activity, selectivity, and cross-resistance pattern.Antiviral Chem Chemother 1993;4(suppl 1): 3–11.Google Scholar
  21. 21.
    Vere Hodge R.A. Famciclovir and penciclovir: the mode of action of famciclovir including its conversion to penciclovir.Antivir Chem Chemother 1993;4(suppl 2): 67–84.Google Scholar
  22. 22.
    Weinberg A, Bate BJ, Masters HB, Schneider SA, Clark JC, Wren CGet al. In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2.Antimicrob Agents Chemother 1992;36(9): 2037–2038.PubMedGoogle Scholar
  23. 23.
    Spruance SL, Stewart JC, Rowe NH, McKeough MB, Wenerstrom G, Freeman DJ. Treatment of recurrent herpes simplex labialis with oral acyclovir.J Infect Dis 1990;161(2): 185–190.PubMedGoogle Scholar
  24. 24.
    Raborn GW, McGaw WT, Grace M, Houle L. Herpes labialis treatment with acyclovir 5 per cent ointment.J Can Dent Assoc 1989;55(2): 135–137.PubMedGoogle Scholar
  25. 25.
    Raborn GW, McGaw WT, Grace M, Percy J, Samuels S. Herpes labialis treatment with acyclovir 5% modified aqueous cream: a double-blind randomized trial.Oral Surg Oral Med Oral Pathol 1989;67(6): 676–679.PubMedCrossRefGoogle Scholar
  26. 26.
    Spruance SL, Rea TL, Thoming C, Tucker R, Saltzman R, Boon R. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group.Jama 1997;277(17): 1374–1379.PubMedCrossRefGoogle Scholar
  27. 27.
    Lin L, Chen XS, Cui PG, Wang JB, Guo ZP, Lu NZ, et al. Topical application of penciclovir cream for the treatment of herpes simplex facialis/labialis: a randomized, double-blind, multicentre, aciclovir-controlled trial.J Dermatology Treat 2002; 13(2): 67–72.CrossRefGoogle Scholar
  28. 28.
    Femiano F, Gombos F, Scully C. Recurrent herpes labialis: efficacy of topical therapy with penciclovir compared with acyclovir (aciclovir).Oral Dis 2001;7(1): 31–33.PubMedCrossRefGoogle Scholar
  29. 29.
    Denavir package insert. Available from URL: Accessed 15st September 2005.Google Scholar
  30. 30.
    Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV-and CMV-seropositive subjects.J Clin Pharmacol 1999;39(8): 800–804.PubMedCrossRefGoogle Scholar
  31. 31.
    Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.Clin Pharmacol Ther 2002;72(2): 142–150.PubMedCrossRefGoogle Scholar
  32. 32.
    Brown F, Banken L, Saywell K, Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive colunteers.Clin Pharmacokinet 1999; 37(2): 167–176.PubMedCrossRefGoogle Scholar
  33. 33.
    Razonable RR, Paya CV. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.Expert Rev Anti, Infect Ther 2004; 2(1): 27–41.CrossRefGoogle Scholar
  34. 34.
    Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou Pet al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.N Engl J Med 2002; 346(15): 1119–1126.PubMedCrossRefGoogle Scholar
  35. 35.
    Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander Bet al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.Am J Transplant 2004; 4(4): 611–620.PubMedCrossRefGoogle Scholar
  36. 36.
    Humar A, Mazzulli T, Moussa G, Razonable RR, Paya CV, Pescovitz MDet al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients.Am J Transplant 2005; 5(5): 1065–1070.PubMedCrossRefGoogle Scholar
  37. 37.
    Valcyte package insert. Available from URL: Accessed 15th September 2005.Google Scholar
  38. 38.
    Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.Transplantation 2005; 79(1): 85–90.PubMedCrossRefGoogle Scholar
  39. 39.
    Bueno J, Ramil C, Green M. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients.Paediatr Drugs 2002; 4(5): 279–290.PubMedGoogle Scholar
  40. 40.
    Pescovitz MD. Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients.Transpl Infect Dis 1999; 1 Suppl 1: 31–34.PubMedGoogle Scholar
  41. 41.
    Kimberlin DW, Lin CY, Sanchez PJ, Demmler GJ, Dankner W, Shelton Met al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial.J Pediatr 2003; 143(1): 16–25.PubMedCrossRefGoogle Scholar
  42. 42.
    Hengge UR, Benninghoff B, Ruzicka T, Goos M. Topical immunomodulators—progress towards treating inflammation, infection, and cancer.Lancet Infect Dis 2001; 1(3): 189–198.PubMedCrossRefGoogle Scholar
  43. 43.
    Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential.Clin Exp Dermatol 2002; 27(7): 571–577.PubMedCrossRefGoogle Scholar
  44. 44.
    Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators.J Antimicrob Chemother 2001; 48(6): 751–755.PubMedCrossRefGoogle Scholar
  45. 45.
    Cates W, Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel.Sex Transm Diss 1999; 26(4 Suppl): S2–7.CrossRefGoogle Scholar
  46. 46.
    Stone KM. Human papillomavirus infection and genital warts: update on epidemiology and treatment.Clin Infect Dis 1995; 20 Suppl 1: S91–97.PubMedGoogle Scholar
  47. 47.
    Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto Jet al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.J Natl Cancer Inst 1995; 87(11): 796–802.PubMedCrossRefGoogle Scholar
  48. 48.
    Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM, Jr. Treatment of genital warts with an immuneresponse modifier (imiquimod).J Am Acad Dermatol 1998; 38(2 Pt 1): 230–239.PubMedCrossRefGoogle Scholar
  49. 49.
    Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL,et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human Papilloma Virus.Arch Dermatol 1998; 134(1): 25–30.PubMedCrossRefGoogle Scholar
  50. 50.
    Garland SM, Sellors JW, Wikstrom A, Petersen CS, Aranda C, Aractingi Set al. Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts—results of an open-label, multicentre Phase IIIB trial.Int J STD AIDS 2001; 12(11): 722–729.PubMedCrossRefGoogle Scholar
  51. 51.
    Tyring SK, Arany I, Stanley MA, Tomai MA, Miller RL, Smith MHet al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod.J Infect Dis 1998; 178(2): 551–555.PubMedGoogle Scholar
  52. 52.
    Gollnick H, Barasso R, Jappe U, Ward K, Eul A, Carey-Yard M,et al. Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day.Int J STD AIDS 2001; 12(1): 22–28.PubMedCrossRefGoogle Scholar
  53. 53.
    Moresi JM, Herbert CR, Cohen BA. Treatment of anogenital warts in children with topical 0.05% podofilox gel and 5% imiquimod cream.Pediatr Dermatol 2001; 18(5): 448–450; discussion 452.PubMedCrossRefGoogle Scholar
  54. 54.
    Schaen L, Mercurio MG. Treatment of human papilloma virus in a 6-month-old infant with imiquimod 5% cream.Pediatr Dermatol 2001; 18(5): 450–452.PubMedCrossRefGoogle Scholar
  55. 55.
    Hengge UR, Esser S, Schultewolter T, Behrendt C, Meyer T, Stockfleth Eet al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum.Br J Dermatol 2000; 143(5): 1026–1031.PubMedCrossRefGoogle Scholar
  56. 56.
    Oster-Schmidt C. Imiquimod: a new possibility for treatment-resistant verrucae planae.Arch Dermatol 2001; 137(5): 666–667.PubMedGoogle Scholar
  57. 57.
    Sparling JD, Checketts SR, Chapman MS. Imiquimod for plantar and periungual warts.Cutis 2001; 68(6): 397–399.PubMedGoogle Scholar
  58. 58.
    Syed TA, Goswami J, Ahmadpour OA, Ahmad SA. Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo-controlled, double-blind study.J Dermatol 1998; 25(5): 309–313.PubMedGoogle Scholar
  59. 59.
    Schacker TW, Conant M, Thoming C, Stanczak T, Wang Z, Smith M. Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study.Antimicrob Agents Chemother 2002; 46(10): 3243–3248.PubMedCrossRefGoogle Scholar
  60. 60.
    Aldara package insert. Available from URL: Accessed 15th September 2005.Google Scholar
  61. 61.
    Katz DH, Marcelletti JF, Pope LE, Khalil MH, Katz LR, McFadden R. n-docosanol: broad spectrum anti-viral activity against lipid-enveloped viruses.Ann N Y Acad Sci 1994; 724: 472–488.PubMedCrossRefGoogle Scholar
  62. 62.
    Product Information: Abreva (TM), docosanol 10% topical cream. In. San Diego, CA: Anavir Pharmaceuticals.Google Scholar
  63. 63.
    Katz DH, Marcelletti JF, Khalil MH, Pope LE, Katz LR. Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex.Proc Natl Acad Sci USA 1991; 88(23): 10825–10829.PubMedCrossRefGoogle Scholar
  64. 64.
    Alrabiah FA, Sacks SL. New antiherpesvirus agents. Their targets and therapeutic potential.Drugs 1996; 52(1): 17–32.PubMedCrossRefGoogle Scholar
  65. 65.
    Sacks SL, Thisted RA, Jones TM, Barbarash RA, Mikolich DJ, Ruoff GEet al. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial.J Am Acad Dermatol 2001; 45(2): 222–230.PubMedCrossRefGoogle Scholar
  66. 66.
    Scolaro MJ, Gunnill LB, Pope LE, Khalil MH, Katz DH, Berg JE. The antiviral drug docosanol as a treatment for Kaposi's sarcoma lesions in HIV type 1-infected patients: a pilot clinical study.AIDS Res Hum Retroviruses 2001; 17(1): 35–43.PubMedCrossRefGoogle Scholar
  67. 67.
    De Clercq E. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster.Biochem Pharmacol 2004; 68(12): 2301–2315.PubMedCrossRefGoogle Scholar
  68. 68.
    De Clercq E, Descamps J, De Somer P, Barr PJ, Jones AS, Walker RT. (E)-5-(2-Bromovinyl)-2′-deoxyuridine: a potent and selective anti-herpes agent.Proc Natl Acad Sci USA 1979; 76(6): 2947–2951.PubMedCrossRefGoogle Scholar
  69. 69.
    Allaudeen HS, Kozarich JW, Bertino JR, De Clercq E. On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2′-deoxyuridine.Proc Natl Acad Sci U S A 1981; 78(5): 2698–2702.PubMedCrossRefGoogle Scholar
  70. 70.
    Fyfe JA. Differential phosphorylation of (E)-5-(2-bromovinyl)=2′-deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus.Mol Pharmacol 1982; 21(2): 432–437.PubMedGoogle Scholar
  71. 71.
    Ayisi NK, De Clercq E, Wall RA, Hughes H, Sacks SL. Metabolic fate of (E)-5-(2-bromovinyl)-2′-deoxyuridine in herpes simplex virus- and mock-infected cells.Antimicrob Agents Chemother 1984; 26(5): 762–765.PubMedGoogle Scholar
  72. 72.
    Wutzler P, De Clercq E, Wutke K, Farber I. Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial.J Med Virol 1995; 46(3): 252–257.PubMedCrossRefGoogle Scholar
  73. 73.
    Heidl M, Scholz H, Dorffel W, Hermann J. Antiviral therapy of varicella-zoster virus infection in immunocompromised children—a prospective randomized study of acyclovir versus brivudin.Infection 1991; 19(6): 401–405.PubMedCrossRefGoogle Scholar
  74. 74.
    Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study.Antiviral Res 2003; 59(1): 49–56.PubMedCrossRefGoogle Scholar
  75. 75.
    Wassilew S. Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients. A randomized, double-blind, multinational study.J Eur Acad Dermatol Venereol 2005; 19(1): 47–55.PubMedCrossRefGoogle Scholar
  76. 76.
    Maudgal PC, De Clercq E. Bromovinyldeoxyuridine treatment of herpetic keratitis clinically resistant to other antiviral agents.Curr Eye Res 1991; 10 Suppl: 193–199.PubMedCrossRefGoogle Scholar
  77. 77.
    Panda A, Das GK, Khokhar S, Rao V. Efficacy of four antiviral agents in the treatment of uncomplicated herpetic keratitis.Can J Ophthalmol 1995; 30(5): 256–258.PubMedGoogle Scholar
  78. 78.
    Marquardt H, Westendorf J, De Clercq E, Marquardt H. Potent anti-viral 5-(2-bromovinyl) uracil nucleosides are inactive at inducing gene mutations in Salmonella typhimurium and V79 Chinese hamster cells and unscheduled DNA synthesis in primary rat hepatocytes.Carcinogenesis 1985; 6(8): 1207–1209.PubMedCrossRefGoogle Scholar
  79. 79.
    Keizer HJ, De Brujin EA, Tjaden UR, De Clercq E. Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2′-deoxyuridine.J Cancer Res Clin Oncol 1994; 120(9): 545–549.PubMedCrossRefGoogle Scholar
  80. 80.
    Okuda H, Nishiyama T, Ogura K, Nagayama S, Ikeda K, Yamaguchi S,et al. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.Drug Metab Dispos 1997; 25(5): 270–273.Google Scholar
  81. 81.
    Okuda H, Ogura K, Kato A, Takubo H, Watabe T. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.J Pharmacol Exp Ther 1998; 287(2): 791–799.PubMedGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2006

Authors and Affiliations

  • Nahed Abdel-Haq
    • 2
    • 1
  • Pimpanada Chearskul
    • 2
    • 1
  • Hossam Al-Tatari
    • 2
    • 1
  • Basim Asmar
    • 2
    • 1
  1. 1.Carman and Ann Adams Department of PediatricsWayne State University, School of MedicineDetroit
  2. 2.Division of Infectious DiseasesChildren's Hospital of MichiganDetroit

Personalised recommendations